ATL 101 - Telix Pharmaceuticals
Alternative Names: 177Lu-J591; 90Y-J591; Anti-PSMA monoclonal antibody J591; Anti-PSMA-monoclonal-antibody-J-591-Lu-177; huJ 591; J 591; J-591-Lu-177; Lu-177-J591; Lu-177-MLN-591; Lutetium-177-labelled anti-PSMA monoclonal antibody J591; Lutetium-177-labelled-J-591; Lutetium-177labelled-MLN-591; MLN 591RL; MLN591; Monoclonal antibody J591; Monoclonal-antibody-J-591-Lu-177; muJ591; Radiolabelled J591; Radiolabelled MLN591Latest Information Update: 25 Aug 2023
At a glance
- Originator Cornell University
- Developer BZL Biologics; Telix Pharmaceuticals; Weill Cornell Medical College
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer; Solid tumours
Most Recent Events
- 27 Feb 2023 Discontinued - Phase-I for Prostate cancer (Neoadjuvant therapy) in USA (IV)
- 27 Feb 2023 Discontinued - Phase-I for Solid tumours (Metastatic disease) in USA (IV)
- 27 Feb 2023 Discontinued - Phase-I/II for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (IV)